The epilepsy market size is projected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is estimated to record a CAGR of 4.1% during 2022–2030. Key factors driving the market growth are rising prevalence of epilepsy and increasing investments in development of epilepsy therapies. However, recall of products may hinder the market growth to a certain extent.
Epilepsy also known as seizure disorder, is a chronic noncommunicable disease that affects brain. Epilepsy affects people of all races, ethnic backgrounds, genders, and ages. According to the Centers for Disease Control and Prevention, it is estimated that 1.2% of people in the United States have active epilepsy.
Epilepsy may occur due to some genetic disorder or may be due to some acquired brain injury, such as a trauma or stroke. According to recent report published by the World Health Organization (WHO) in February 2023, epilepsy accounts for a significant share of the worldwide disease burden, affecting nearly fifty million people across the world. Moreover, 4–10 persons per 1,000 individuals are estimated to have active epilepsy (i.e., with the need for treatment or continuing seizures). Nearly 5 million people are diagnosed with epilepsy every year. High-income countries are estimated to report high epilepsy at a rate of 49 per 100,000 people annually. This number can reach 139 per 100,000 individuals in low- and middle-income countries. An upsurge in epilepsy incidence can be attributed to the higher count of road traffic injuries and birth-related injuries, and the elevated risk of endemic conditions such as neurocysticercosis or malaria. The WHO also states that approximately 70% of individuals with epilepsy can become seizure-free with the use of medications.
Treatments to control epilepsy include anti-epileptic medications, special diets (in addition to anti-seizure medications), and surgery; however, anti-epileptic drug therapy is the primary treatment prescribed for most patients. Thus, the rising prevalence of epilepsy worldwide drives market growth.
The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below
Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment.
Numerous awareness campaigns are conducted by organizations globally to spread awareness regarding the disease condition and available treatment. In the US, Epilepsy Awareness Day or Purple Day is observed on March 26 every year to raise public understanding of the brain disorder, along with eliminating its fear and stigma. Similarly, November is reserved as National Epilepsy Awareness Month (NEAM) in the US every year to educate people about the condition and symptoms of epilepsy and raise funds for research related to managing this disease. The Epilepsy Foundation selects a theme that encourages people to collaborate and act to promote awareness and funds for epilepsy. In November 2021, the foundation launched the #RemoveTheFilter social media campaign to reduce fear associated with epilepsy and bring hope to those suffering from the condition.
Moreover, in partnership with SK Life Science Inc., the Epilepsy Foundation introduced a 30-minute on-demand course for people to learn the essentials of seizure first aid. The UK Sudden Unexpected Death in Epilepsy (SUDEP) Awareness Day is celebrated on October 23. The SUDEP action leads the international epilepsy community to recognize and raise awareness about sudden and unexpected death due to epilepsy. Thus, such initiatives and awareness campaigns increase epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.
Key segments that contributed to the derivation of the epilepsy market analysis are type, route of administration, treatment type, age group, and distribution channel.
The geographic scope of the epilepsy market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.
In North America, the epilepsy market is currently experiencing exponential growth during the forecast years. The US market dominates the global epilepsy market in 2022. The burgeoning number of cases of neurological diseases such as Alzheimer's disease, increasing awareness about neurological disorders, favourable results obtained in research activities, and growing investments in developing epilepsy drugs are among the main factors driving the overall epilepsy market growth in the US. In March 2020, Neurelis, Inc. announced the commercial availability of VALTOCO (diazepam nasal spray) to treat stereotypic, intermittent episodes of frequent seizures (i.e., acute repetitive seizures and seizure clusters) that are different from a usual seizure pattern observed in pediatric and adult patients. Similarly, in March 2022, the FDA approved Ztalmy (ganaxolone) to treat seizures related to cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2 and older.
In August 2021, the CDC Epilepsy Program selected the Epilepsy Foundation as its funding recipient under a new cooperative agreement: Improving Systems of Care, Epilepsy Education, and Health Outcomes through National and Community Partnerships. The US$ 17.5 million in federal funds that would be allotted over the next 5 years would support the work of the Epilepsy Foundation and its partners in creating and maintaining a robust public health infrastructure, advancing health equity, improving quality of life, and achieving the best outcomes for all people living with the epilepsies. Therefore, the increasing prevalence of epilepsy, new drug launches, and research and funding initiatives bolster the epilepsy market size in the US.
The regional trends and factors influencing the Epilepsy Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Epilepsy Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 7.7 Billion |
| Market Size by 2030 | US$ 10.7 Billion |
| Global CAGR (2022 - 2030) | 4.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Epilepsy Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Epilepsy Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The epilepsy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for innovations, business expansion, and strategies:
The “Epilepsy Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering the following areas:
The market is expected to register a CAGR of 4.10% during 2023–2031.
Abbott Laboratories, Pfizer Inc., Eisai Co Ltd., UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS
The high-throughput genetic sequencing technique enables a faster and more comprehensive analysis of DNA, thereby aiding the identification of genetic causes of conditions such as epilepsy are likely to remain a key trend in the market.
The rising prevalence of epilepsy and increasing investments in development of epilepsy therapies are the major factors fuelling the market growth of epilepsy over the years.
North America dominated the epilepsy market in 2023